KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Assets (2016 - 2025)

Historic Assets for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $112.5 billion.

  • Eli Lilly's Assets rose 4289.02% to $112.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $112.5 billion, marking a year-over-year increase of 4289.02%. This contributed to the annual value of $112.5 billion for FY2025, which is 4289.02% up from last year.
  • Latest data reveals that Eli Lilly reported Assets of $112.5 billion as of Q4 2025, which was up 4289.02% from $114.9 billion recorded in Q3 2025.
  • Eli Lilly's 5-year Assets high stood at $114.9 billion for Q3 2025, and its period low was $46.8 billion during Q1 2021.
  • Moreover, its 5-year median value for Assets was $56.4 billion (2023), whereas its average is $66.0 billion.
  • As far as peak fluctuations go, Eli Lilly's Assets plummeted by 155.91% in 2022, and later skyrocketed by 5201.71% in 2025.
  • Eli Lilly's Assets (Quarter) stood at $48.8 billion in 2021, then increased by 1.4% to $49.5 billion in 2022, then grew by 29.33% to $64.0 billion in 2023, then rose by 22.98% to $78.7 billion in 2024, then soared by 42.89% to $112.5 billion in 2025.
  • Its Assets stands at $112.5 billion for Q4 2025, versus $114.9 billion for Q3 2025 and $100.9 billion for Q2 2025.